Immunotoxin

From Wikipedia, the free encyclopedia
Jump to: navigation, search

An immunotoxin is a human-made protein that consists of a targeting portion linked to a toxin. When the protein binds to that cell, it is taken in through endocytosis, and the toxin kills the cell.[1] They are used for the treatment of some kinds of cancer and a few viral infections.

Design[edit]

These chimeric proteins are usually made of a modified antibody or antibody fragment, attached to a fragment of a toxin. The targeting portion is composed of the Fv portion of an antibody that targets a specific cell type.[2] The toxin is usually a cytotoxic protein derived from a bacterial or plant protein, from which the natural binding domain has been removed so that the Fv directs the toxin to the antigen on the target cell.[1]

Sometimes recombinant fusion proteins containing a toxin and a growth factor are also referred to as recombinant immunotoxins, although they do not contain an antibody fragment. A more specific name for this latter kind of protein is recombinant fusion toxin.

Production[edit]

They were originally produced by attaching the antibody to the toxin using a chemical linker.[citation needed] They are now made using recombinant DNA techniques, are produced in bacteria like E. coli or yeast like P. pastoris and are called recombinant immunotoxins.

Function[edit]

The antibody (or other targeting moiety) binds to an antigen on the target cell and the toxin then enters and kills the cell.

Clinical application[edit]

The best clinical success has been achieved in treating patients with refractory hairy cell leukemia.[citation needed] These patients were treated with the recombinant immunotoxin, BL22, which targets the CD22 cell surface receptor, which is highly expressed on these leukemic cells. In two uncontrolled clinical studies, about half of participants achieved a complete response after BL22 treatment.[3] This therapeutic has been superseded by HA22, a slightly modified version.

A recent Phase I study of Resimmune found an 87.5% response rate in a subgroup of eight patients with cutaneous T cell lymphoma.[4] This subgroup was Stage IB-IIB with mSWAT scores of less than 50. The complete response rate was 50% (two of which are over 60 months duration and could represent cures).

See also[edit]

References[edit]

  1. ^ a b Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007). "Immunotoxin treatment of cancer". Annu. Rev. Med. 58: 221–37. doi:10.1146/annurev.med.58.070605.115320. PMID 17059365. 
  2. ^ Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (July 2006). "Immunotoxin therapy of cancer". Nat. Rev. Cancer 6 (7): 559–65. doi:10.1038/nrc1891. PMID 16794638. 
  3. ^ Kreitman RJ, Wilson WH, Bergeron K, et al (July 2001). "Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia". N. Engl. J. Med. 345 (4): 241–7. doi:10.1056/NEJM200107263450402. PMID 11474661. 
  4. ^ [1] Angimmune: Clinical Trials: Identification of a Cutaneous T-Cell Lymphoma (CTCL) Subgroup Experiencing a High Treatment Response Rate: Paragraph 1

External links[edit]